MedTrace Logo

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

NCT03583099 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2004

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

A prospective, multicenter study including a cross-section validation to define sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant Chronic Obstructive Pulmonary Disease (COPD), and its impact on clinical care across a broad range of primary care settings in a cluster randomized controlled clinical trial.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

OTHER

COPD plus CAPTURE education and patient-level information

Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.

OTHER

COPD Education Only

Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Michigan

    collaborator OTHER

  • National Jewish Health

    collaborator OTHER

  • Wake Forest University Health Sciences

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • High Plains Research Network

    collaborator NETWORK

  • L.A. Net Community Health Resource Network

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • University of Kentucky

    collaborator OTHER

  • University of Minnesota

    collaborator OTHER

  • COPD Foundation

    collaborator OTHER

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Fernando J Martinez, MD, MS · Weill Medical College of Cornell University

  • MeiLan Han, MD, MS · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-12
Primary Completion
2023-04-07
Completion
2023-04-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03583099 on ClinicalTrials.gov